- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00378365
Acute Promyelocytic Leukemia 2006 (APL)
A Randomized Trial Assessing the Role of Arsenic Trioxide and/or ATRA During Consolidation Course in Newly Diagnosed Acute Promyelocytic Leukemia (APL)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Definition: Extended description of the protocol, including information not already contained in other fields, such as comparison(s) studied.
APL is a specific type of acute myeloid leukemia (AML) characterized by its morphology (M3 or M3v in the FAB classification), t(15;17) translocation leading to PML-RARa fusion gene, and by a specific coagulopathy combining D.I.C., fibrinolysis and non specific proteolysis. ATRA can differentiate APL blasts in VITRO and in vivo. The combination of ATRA and anthracycline based chemotherapy yields CR rates greater than 90% in newly diagnosed APL. With early introduction of anthracycline AraC chemotherapy during induction treatment, and maintenance combining continuous 6MP and MTX to intermittent ATRA, the relapse risk in APL therefore now appears to be in the range of 10 to 15%.
Nevertheless, 5 to 10% of the patients do not achieve CR and 10% to 15% still relapse. Another subset of patients (5 to 7% in APL 93 trial including 17% of patients aged greater than 65 years) die in CR, from complications of the consolidation treatment phase, mainly from infection during chemotherapy induced aplasia. Failure to achieve CR with current treatment approaches is almost exclusively due to early death during induction treatment. Causes of death are predominantly bleeding, ATRA syndrome and less often infection. Early deaths predominate in elderly patients and patients with high WBC counts. Reducing the amount of chemotherapy administered to newly diagnosed APL patients diminishes this toxicity. The Spanish PETHEMA group reported results of two successive phase II trials in newly diagnosed APL with ATRA and chemotherapy with intercalating agents (idarubicin and mitoxantrone) without AraC followed by maintenance combining ATRA and low dose chemotherapy (LPA96 and LPA99 trials). Results appeared similar to those of the best arm of APL 93 trial, but with less toxicity and only 2 to 3 % death in CR were seen, including in elderly patients.
Arsenic trioxide (As2O3 or ATO) is an effective agent in relapsing or refractory APL, which induced 85% hematological and 79% molecular CR rates in a pivotal US study. The interest of ATO in the front-line therapy of newly-diagnosed APL has been strongly suggested in three studies which showed high complete remission rate, low incidence of relapse and limited toxicity.
In this study, patients will be stratified based on age (≤ 70 years and > 70 years) and WBC count at diagnosis (WBC<10.000/mm3 and >10.000 /mm3).
-Patients aged 70 years or less with WBC<10.000/mm3.
In this population (about 70 % of APL) the best treatment group of APL2000 trial (ATRA with early introduction of anthracycline-AraC chemotherapy but where Idarubicin will be substituted for Daunorubicin, followed by 2 anthracycline-AraC consolidation courses and maintenance combining continuous chemotherapy and intermittent ATRA) will be compared to the same regimen, but without AraC during consolidation courses which will be replaced by:
- either ATO
or ATRA It is hoped that the investigational arms will further increase the event-free survival at 2 years, with reduced toxicity and without increasing the relapse rate by comparison with a classical anthracycline-AraC consolidation regimen.
- Patients aged 70 years or less with WBC>10.000/mm3 Patients ages 70 years or less with initial WBC counts > 10000/mm3 (ie very high counts for APL), which represent about 20% of APL, remain at relatively high risk of relapse even with the current reference treatment. The main objective of the study will be to test the addition of ATO during consolidation courses to our current standard ATRA and chemotherapy regimen. Patients will receive the best treatment group of APL 2000 trial (but where Idarubicin will be substituted for Daunorubicin) with or without ATO during the 2 consolidation cycles.
- Patients older than 70 years with WBC<10.000 /mm3. Elderly patients with initial WBC ≤ 10000/m3 (about 8% of APL) and no contra indication to this treatment will receive a regimen with reduced cumulative dose of chemotherapy but addition of ATO during consolidation courses and during the first year of maintenance treatment. The main purpose of this non randomized part of the trial is to reduce the early death mortality and death in CR observed in elderly patients, without increasing the relapse rate.
- Patients older than 70 years with WBC>10.000 /mm3. Elderly patients with initial WBC > 10000/m3 (about 2 to 3% of APL) and no contra indication to intensive regimen will receive the same regimen as those with low WBC but with moderate doses of Aracytine during the induction and during the first consolidation course. The main purpose of this non randomized part of the trial is to reduce the early death mortality and death in CR observed in elderly patients, without increasing the relapse rate.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Lionel ADES, MD
- Phone Number: +33(0)-148 95 70 55
- Email: Lionel.ades@avc.aphp.fr
Study Locations
-
-
-
Bobigny, France, 93000
- Recruiting
- CHU Avicenne
-
Contact:
- Lionel ADES, MD,PhD
- Phone Number: +33(0)- 148 95 70 55
- Email: Lionel.ades@avc.aphp.fr
-
Principal Investigator:
- Lionel ADES, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of APL based on morphological grounds, which will have to be confirmed by the presence of t(15;17) and/or PML-RARA rearrangement with characterization of the bcr subtype (PML-RAR characterization).
- Untreated patients.
- No contraindication to intensive chemotherapy (especially well documented cardiac contraindication to idarubicin).
- In female patients: absence of pregnancy and adequate contraceptive methods (due to teratogenetic effects of ATRA in early pregnancy).
- Absence of Hypersensitivity to Arsenic derivatives.
- No QT interval prolongation or complete atria-ventricular block.
- Written informed consent.
Exclusion Criteria:
- Patients already treated.
- Patients with contraindication to intensive chemotherapy, especially well documented cardiac contraindication to Idarubicin.
- In female patients: pregnancy or absence of adequate contraceptive Methods
- QT interval prolongation or complete atria-ventricular block.
- Hypersensitivity to Arsenic derivatives.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
Arsenic trioxide
|
Arsenic trioxide
ATRA
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
For Patients aged 70 years or less with WBC<10.000/mm3, The primary end point will be event free survival at 2 years from CR achievement
Time Frame: during de study
|
For Patients aged 70 years or less with WBC<10.000/mm3,
The primary end point
|
during de study
|
For patients older than 70 years with WBC>10.000 /mm3, The primary end point will be EFS at 2 years from diagnosis
Time Frame: during the study
|
For patients older than 70 years with WBC>10.000
/mm3, The primary end point will be EFS at 2 years from diagnosis
|
during the study
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
For Patients aged 70 years or less with WBC<10.000/mm3 :
Time Frame: during the study
|
For Patients aged 70 years or less with WBC<10.000/mm3
:
|
during the study
|
Relapse (molecular or hematological).
Time Frame: during the study
|
Relapse (molecular or hematological).
|
during the study
|
Kinetics of decrease of PML-RARA transcript level during and after consolidation course.
Time Frame: during the study
|
Kinetics of decrease of PML-RARA transcript level during and after consolidation course.
|
during the study
|
Survival at 2 years.
Time Frame: during the study
|
Survival at 2 years.
|
during the study
|
Side effects of the treatment, including treatment-related mortality and morbidity of consolidation treatment.
Time Frame: during th study
|
Side effects of the treatment, including treatment-related mortality and morbidity of consolidation treatment.
|
during th study
|
Days on antibiotics, transfusion requirement and nights spent in Hospital
Time Frame: during the study
|
Days on antibiotics, transfusion requirement and nights spent in Hospital
|
during the study
|
For Patients aged 70 years or less with WBC>10.000/mm3
Time Frame: during the study
|
For Patients aged 70 years or less with WBC>10.000/mm3
|
during the study
|
event free survival at 2 years from CR achievement
Time Frame: during the study
|
event free survival at 2 years from CR achievement
|
during the study
|
Side effects of the treatment, including treatment-related mortality and morbidity of consolidation treatment.
Time Frame: during the study
|
Side effects of the treatment, including treatment-related mortality and morbidity of consolidation treatment.
|
during the study
|
For Patients older than 70 years with WBC<10.000 /mm3
Time Frame: during the study
|
For Patients older than 70 years with WBC<10.000
/mm3
|
during the study
|
Kinetics of decrease of PML-RARA transcript level during and after consolidation course.
Time Frame: during the study
|
Kinetics of decrease of PML-RARA transcript level during and after
|
during the study
|
Relapse and survival at 2 years.
Time Frame: during the study
|
Relapse and survival at 2 years.
|
during the study
|
Side effects of the treatment, including mortality and morbidity of consolidation treatment.
Time Frame: during the study
|
Side effects of the treatment, including mortality and morbidity of
|
during the study
|
For patients older than 70 years with WBC>10.000 /mm3
Time Frame: during the study
|
For patients older than 70 years with WBC>10.000
/mm3
|
during the study
|
Collaborators and Investigators
Investigators
- Principal Investigator: Lionel ADES, MD,PhD, Assistance Publique - Hôpitaux de Paris
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- P050604
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Leukemia, Promyelocytic, Acute
-
German AML Cooperative GroupUnknownRelapsed Acute Promyelocytic Leukemia | Refractory Acute Promyelocytic LeukemiaGermany
-
Christian Medical College, Vellore, IndiaUnknownRelapsed Acute Promyelocytic LeukemiaIndia
-
South China Children's Leukemia GroupCompletedChildhood Acute Promyelocytic LeukemiaChina
-
Instituto Nacional de Cancerologia de MexicoCompletedPromyelocytic Leukemia, AcuteMexico
-
PETHEMA FoundationCompletedAcute Promyelocytic LeukemiaSpain
-
Peking University People's HospitalMinistry of Science and Technology of the People´s Republic of ChinaNot yet recruitingAcute Promyelocytic Leukaemia
-
Grupo Argentino de Tratamiento de la Leucemia AgudaRecruiting
-
Children's Oncology GroupNational Cancer Institute (NCI)Active, not recruitingAcute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARAUnited States, Canada, Saudi Arabia, Puerto Rico, Australia, New Zealand
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Acute Promyelocytic Leukemia With PML-RARAUnited States
-
The University of Hong KongRecruitingAcute Promyelocytic LeukemiaHong Kong
Clinical Trials on Arsenic trioxide
-
Ruijin HospitalRecruitingRefractory Solid TumorsChina
-
CTI BioPharmaTerminatedMultiple Myeloma and Plasma Cell NeoplasmUnited States
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)CompletedProstate CancerUnited States
-
National Cancer Institute (NCI)CompletedLymphoma | LeukemiaUnited States, Canada, Australia
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedLymphoma | Leukemia | Multiple Myeloma and Plasma Cell NeoplasmUnited States
-
Southwest Oncology GroupNational Cancer Institute (NCI)CompletedTesticular Germ Cell Tumor | Extragonadal Germ Cell TumorUnited States
-
Washington University School of MedicineNational Cancer Institute (NCI)Completed
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Withdrawn
-
Northwestern UniversityNational Cancer Institute (NCI)TerminatedLymphomaUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)Completed